Panasonic is finalizing a substantial investment in troubled medical and camera company Olympus, according to reports from Japan. The Kyodo news agency is saying that Panasonic will invest around ￥500bn ($630m) in the business - making it the company's largest shareholder. Panasonic has little presence in the medical market, so it seems likely the move is as much about ensuring the continuation of its partner in the Micro Four Thirds collaboration, which could have been jeopardized if the much-needed tie-up had been with a rival camera maker.

Earlier reports from Kyodo suggested that Olympus will announce an updated post-scandal business plan this Friday (June 8th), which could see a more formal announcement of such a deal. Olympus has repeatedly said it would seek a partner as it attempts to recover from an accounting scandal that had seen its share price plunge as it acknowledged losses of $1.7bn had been covered-up. Fujifilm, which also has extensive medical interests, was long rumored to be interested in a partnership.

涨价理由不充分
本帖由移动终端发布

松下的镜头会涨价吗？

M43方向很好，但感觉单是奥家或松家势单力薄，难以推动普及，两家只能合作抗衡尼康佳能现有的单反格局。

腾讯财经讯 北京时间6月7日下午消息，此前日本共同社有报道称，松下准备向奥林巴斯投资500亿日元（约合6.3亿美元）。但当地时间6月7日，松下总裁否认了公司有关投资奥林巴斯的消息。

据报道，日本松下总裁大坪文雄（Fumio Ohtsubo）告诉路透社的记者说，公司没有投资奥林巴斯公司的计划。大坪文雄说到，“我不知道消息是从哪儿来的，这完全是子虚乌有。”当被问及到是否会投资奥林巴斯的时候，他一口否决了。

去年，奥林巴斯承认使用了不正当的账务手段来掩盖自20世纪90年代始的一项投资损失。截至三月底时起，奥林巴斯股东权益共占公司总资产的4.6%，远远低于20%的水平，20%的股东权益比一直被广泛地看作是一家公司财政稳定的硬性指标。这驱使着奥林巴斯迫切地想寻找一次资本注入。

为了弥补财务上的诸多问题，奥林巴斯目前正在考虑引入一位战略投资者，诸如索尼、富士、泰尔茂(Terumo Corp)以及松下等名企均在其考虑之列。

然而，松下目前只专注于扩张它自己的医疗保健业务。之前，松下刚公布今年的财务损失，达到※※新高。

M43要涨价基本就属于自取灭亡了

奥林巴斯一直就属于松下财团，就像前几年松下收购三洋一样，财团内部自己玩儿。

涨价不可能的，松下的竞争对手一直就不是奥巴，相反松下入股后奥巴可能会大降。一对好基友从以前的眉来眼去，变成了水乳交融

必然的吧

如同早先km和sony的合作